ES2111167T3 - Compuestos peptidicos. - Google Patents

Compuestos peptidicos.

Info

Publication number
ES2111167T3
ES2111167T3 ES93917902T ES93917902T ES2111167T3 ES 2111167 T3 ES2111167 T3 ES 2111167T3 ES 93917902 T ES93917902 T ES 93917902T ES 93917902 T ES93917902 T ES 93917902T ES 2111167 T3 ES2111167 T3 ES 2111167T3
Authority
ES
Spain
Prior art keywords
peptides
peptide
synthesis
steps
presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917902T
Other languages
English (en)
Inventor
Istvan Toth
William Anthony Gibbons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Application granted granted Critical
Publication of ES2111167T3 publication Critical patent/ES2111167T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LOS PEPTIDOS SINTETICOS SE UTILIZAN MUCHO PARA GENERAR ANTICUERPOS. PARA INDUCIR UN ALTO GRADO DE RESPUESTA A LOS ANTICUERPOS SE SABE QUE CONJUGANDO EL PEPTIDO A UNA PROTEINA PORTADORA (EJ. KLH, BSA) O INCORPORANDOLO EN UNA POLILISINA SE FORMA UN PEPTIDO ANTIGENICO MULTIPLE. SE PUEDEN FORMAR ENLACES BASADOS EN ACIDOS GRASOS. SEGUN LA INVENCION SE PRESENTA UN NUEVO AMINOACIDO LIPIDICO BASADO EN UN SISTEMA DE ENLACE QUE PUEDE AUMENTAR AL MAXIMO LA ANTIGENICIDAD DE UN PEPTIDO SINTETICO CORTO. ESTOS NUEVOS COMPUESTOS SE BASAN POR COMPLETO EN PEPTIDOS Y POR TANTO SE PUEDEN PRODUCIR AUTOMATICAMENTE MEDIANTE ALGUNAS SINTESIS DE PEPTIDOS POR PASOS, PREFERENTEMENTE MEDIANTE UNA SINTESIS DE PEPTIDOS POR PASOS EN FASE SOLIDA. EN LA INVENCION TAMBIEN SE PRESENTA TAL PROCESO.
ES93917902T 1992-07-24 1993-07-23 Compuestos peptidicos. Expired - Lifetime ES2111167T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215780A GB9215780D0 (en) 1992-07-24 1992-07-24 Peptide compounds

Publications (1)

Publication Number Publication Date
ES2111167T3 true ES2111167T3 (es) 1998-03-01

Family

ID=10719254

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917902T Expired - Lifetime ES2111167T3 (es) 1992-07-24 1993-07-23 Compuestos peptidicos.

Country Status (7)

Country Link
US (1) US5882645A (es)
EP (1) EP0652896B1 (es)
AU (1) AU4715493A (es)
DE (1) DE69315842T2 (es)
ES (1) ES2111167T3 (es)
GB (1) GB9215780D0 (es)
WO (1) WO1994002506A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5605894A (en) * 1992-11-12 1994-06-08 Molecular Dynamics, Inc. Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
JP2001502658A (ja) * 1996-04-03 2001-02-27 ペプレサーチ・エー／エス 非樹状中心骨格ペプチド担体
DE69704269T2 (de) 1997-06-11 2001-11-22 School Of Pharmacy, University Of London Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
ATE311202T1 (de) 1998-09-23 2005-12-15 Univ London Pharmacy Kationische dendrimer verbindungen und deren verwendung als oligonucleotid/polynucleotid träger
EP1117677B1 (en) * 1998-09-29 2003-11-12 Statens Serum Institut Ligand presenting assembly (lpa), method of preparation and uses thereof
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9912911D0 (en) 1999-06-04 1999-08-04 Zeneca Ltd Chemical process
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
US6774102B1 (en) * 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002021141A2 (en) * 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
US7314956B2 (en) 2001-08-08 2008-01-01 Vaxim, Inc. Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
WO2003054146A2 (en) 2001-11-14 2003-07-03 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
WO2003070749A2 (en) 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
AU2003219863C1 (en) * 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
IL163668A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Use of peptide-drug conjugation to reduce inter-subject variability ofdrug serum levels
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
US7683025B2 (en) 2002-11-14 2010-03-23 Northwestern University Synthesis and self-assembly of ABC triblock bola peptide amphiphiles
US20040101901A1 (en) * 2002-11-27 2004-05-27 Piotr Tabaczewski Novel lipophilic complexes for insertion of receptors into lipid membranes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
ES2279411T3 (es) * 2003-05-02 2007-08-16 Almar Packaging International Inc. Recipiente para graneles intermedios.
KR101159477B1 (ko) 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물
US9763977B2 (en) 2003-09-16 2017-09-19 Incube Labs, Llc In vitro bio-reactor circuit
US20050063937A1 (en) * 2003-09-16 2005-03-24 Cheng Li Multiple-arm peptide compounds, methods of manufacture and use in therapy
WO2005056576A2 (en) 2003-12-05 2005-06-23 Northwestern University Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
ATE541580T1 (de) 2003-12-05 2012-02-15 Univ Northwestern Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2598251A1 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
WO2007027954A2 (en) * 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
WO2009146885A2 (en) * 2008-06-02 2009-12-10 Spiderbiotech S.R.L. Lipidated antibacterial peptides
WO2010033923A2 (en) * 2008-09-21 2010-03-25 Wayne State University Genus-wide chlamydial peptide vaccine antigens
US8883967B2 (en) 2009-03-27 2014-11-11 Kansas State University Research Foundation Branched amphipathic oligo-peptides that self-assemble into vesicles
AU2010236584A1 (en) 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
WO2014026033A1 (en) 2012-08-08 2014-02-13 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
RS60135B1 (sr) * 2013-03-18 2020-05-29 Statens Seruminstitut Vakcine protiv hlamidije sp.
JP6633523B2 (ja) * 2013-12-01 2020-01-22 ユニバーシティ オブ コペンハーゲン Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
WO2017075653A1 (en) * 2015-11-04 2017-05-11 University Of The Sunshine Coast Chlamydia antigens and uses thereof
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11560419B2 (en) * 2018-12-21 2023-01-24 West Virginia University Targeting tumor microenvironments with recombinant prokaryotic collagen-like proteins
CN118121547B (zh) * 2024-03-06 2024-10-01 西南大学 一种多肽导向分子嵌入式脂质复合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052699A (es) * 1963-12-03
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope

Also Published As

Publication number Publication date
DE69315842D1 (de) 1998-01-29
DE69315842T2 (de) 1998-04-09
EP0652896B1 (en) 1997-12-17
US5882645A (en) 1999-03-16
WO1994002506A1 (en) 1994-02-03
EP0652896A1 (en) 1995-05-17
AU4715493A (en) 1994-02-14
GB9215780D0 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
GB9215780D0 (en) Peptide compounds
ATE290014T1 (de) Festphasen-peptidsynthese
ES2146212T3 (es) Proteinas de union a antigenos trivalentes monoespecificas.
ES2124276T3 (es) Anticuerpos perfeccionados contra plasmodium falciparum.
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
ES2010538A6 (es) Procedimiento para la preparacion de un gen sintetico.
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
DK0644202T3 (da) Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
BR9809656A (pt) Composição imunopotencializante
DE60319350D1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
DK124087D0 (da) Immunogent peptidantigen svarende til plasmodium vivax circumsporozoitprotein
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
IT8319160A0 (it) Procedimento di sintesi di peptidi e agenti di bloccaggio di amminoacidi.
WO2004030616A3 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
ES8702438A1 (es) Un metodo para preparar un peptido
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
DK1621547T3 (da) Konjugater af polypeptidmolekyler og lipider fra malarie præ-erythrocytisk stadie
PT635025E (pt) Processo para preparar proteinas modificadas
ES2083387T3 (es) Peptidos sinteticos y sus mezclas para la deteccion de anticuerpos hiv.
ES2117272T3 (es) Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652896

Country of ref document: ES